Literature DB >> 20483041

Serum disease-associated proteins of ankylosing spondylitis: results of a preliminary study by comparative proteomics.

T Li1, Z Huang, B Zheng, Z Liao, L Zhao, J Gu.   

Abstract

OBJECTIVES: Ankylosing spondylitis (AS) is difficult to diagnose at the early stage since it lacks simple and specific diagnostic indicators. Proteomics is a new enabling technology to screen disease-associated proteins which can be used in diagnostics or therapeutics. This study was performed by using two-dimensional electrophoresis (2-DE) in combination with mass spectrometry to search for disease-associated proteins in the sera of AS patients.
METHODS: Sera from 6 AS patients and 6 healthy volunteers (HVs) were mixed respectively and high-abundance proteins were depleted by Plasma 7 Multiple Affinity Removal System. The protein expression profiles of the sera between the two groups were compared by 2-DE and proteins over/under-expressed in the AS group were identified by mass spectrometry. Two of the identified proteins were then chosen to be verified by using ELISA in the individual sera of 32 AS patients and 32 HVs.
RESULTS: Serum amyloid A, apolipoprotein A (ApoA)-IV, ApoA-IV precursor, haptoglobin 2, ceruloplasmin (Cp) and immunoglobulin superfamily 22 were over-expressed by more than 3-fold in the sera of AS patients compared with HVs. Plasma glutathione peroxidase, similar to complement component 3 and chain A of transthyretin (TTR) were under-expressed in the sera of the AS patients. ELISA experiments showed the same trends in the expression levels of Cp and TTR with 2-DE.
CONCLUSIONS: There were 9 differentially expressed proteins in the sera of the AS group compared with the HV group, which might be candidate AS-associated proteins and might be promising diagnostic indicators or therapeutic targets for AS.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20483041

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  5 in total

Review 1.  Biomarker development for axial spondyloarthritis.

Authors:  Matthew A Brown; Zhixiu Li; Kim-Anh Lê Cao
Journal:  Nat Rev Rheumatol       Date:  2020-06-30       Impact factor: 20.543

2.  Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab.

Authors:  Carrie Wagner; Sudha Visvanathan; Jürgen Braun; Désirée van der Heijde; Atul Deodhar; Benjamin Hsu; Michael Mack; Michael Elashoff; Robert D Inman
Journal:  Ann Rheum Dis       Date:  2011-10-28       Impact factor: 19.103

3.  Serum biomarkers and changes in clinical/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE study.

Authors:  Robert D Inman; Xenofon Baraliakos; Kay-Geert A Hermann; Jürgen Braun; Atul Deodhar; Désirée van der Heijde; Stephen Xu; Benjamin Hsu
Journal:  Arthritis Res Ther       Date:  2016-12-28       Impact factor: 5.156

4.  Inhibition of Complement Retards Ankylosing Spondylitis Progression.

Authors:  Chaoqun Yang; Peipei Ding; Qingkai Wang; Long Zhang; Xin Zhang; Jianquan Zhao; Enjie Xu; Na Wang; Jianfeng Chen; Guang Yang; Weiguo Hu; Xuhui Zhou
Journal:  Sci Rep       Date:  2016-10-04       Impact factor: 4.379

5.  Circulating Retinol-Binding Protein 4 as a Possible Biomarker of Treatment Response for Ankylosing Spondylitis: An Array-Based Comparative Study.

Authors:  Jialing Wu; Xinyu Wu; Zena Chen; Qing Lv; Mingcan Yang; Xuqi Zheng; Qiuxia Li; Yanli Zhang; Qiujing Wei; Shuangyan Cao; Xiaomin Li; Jun Qi; Minjing Zhao; Zetao Liao; Zhiming Lin; Jieruo Gu
Journal:  Front Pharmacol       Date:  2020-03-10       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.